The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2005K-ATP Channels and Their Role in the Survival of Nigral Dopaminergic Neurons
ATP-sensitive potassium (K-ATP) channels are present is numerous tissues including the brain. Their function has been best studied in the pancreatic B-islet cells that participate in the regulation of...
-
Community Fast Track, 2005Use of NR2D-selective NMDA Receptor Modulators in the Treatment of PD
The frontline pharmacological treatment for Parkinson's disease is associated with serious side effects, creating a need for new therapeutic strategies. Recent evidence suggests that selective...
-
Community Fast Track, 2005The role of serotonin neurons in the induction and maintenance of dyskinesias in grafted and L-DOPA-primed animals
Background: Levodopa, the most commonly used medication for patients with Parkinson's disease, is a beneficial therapy, but as the disease progresses it can be the cause of debilitating involuntary...
-
LEAPS, 2005New Small Molecule Inhibiting Agents of Alpha-Synuclein & Lewy Body Formation as Disease-Modifying Treatments for Parkinson's Disease
Parkinson's Disease is pathologically characterized by the presence and accumulation of a protein known as alpha-synuclein. Mutations in alpha-synuclein have been directly linked to PD, and alpha...
-
LEAPS, 2005Development and Optimization of a Regulatable Gene Switch for Gene Therapies of Parkinson’s Disease
Gene therapy holds tremendous potential for the treatment of Parkinson's disease. By using a virus or other DNA delivery system to permanently insert a new gene into critical regions of a Parkinson...
-
Community Fast Track, 2005Specific Inhibition of Nucleation of Alpha-synuclein Aggregation as a Therapeutic Strategy
There is considerable evidence that aggregates of the human brain protein alpha-synuclein are a primary cause of the loss of neurons in Parkinson's disease. We have tried to find out what initiates...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.